Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-derived body composition for optimized carboplatin dosing
NL-OMON56726Recruiting
- Sponsor
- Amphia Ziekenhuis
- Start
- Dec 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of carboplatin in bronchial carcinoma and ovarian cancer, sponsored by Amphia Ziekenhuis. Primary endpoint: Covariate relationship between CT-derived body composition, serum creatinine, and carboplatin pharmacokinetics. Started Dec 2024; status: recruiting.
02
Drugs
carboplatin
03
Conditions
bronchial carcinomaovarian cancer
Beyond the preview
Go deeper on NL-OMON56726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56726.